World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
60727
World Ranking
5253
National Ranking
2834

Robert P. Giugliano publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert P. Giugliano sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 621 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert P. Giugliano D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert P. Giugliano sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert P. Giugliano is affiliated with Brigham and Women's Hospital in the United States. Their research primarily focuses on medicine, with a significant concentration in cardiology and cardiovascular medicine. Their work spans multiple subfields, including cardiology and cardiovascular medicine, surgery, economics and econometrics, endocrinology, diabetes and metabolism, and internal medicine.

Their scholarly output centers around several key topics, notably lipoproteins and cardiovascular health, atrial fibrillation management and outcomes, antiplatelet therapy and cardiovascular diseases, health systems, economic evaluations, and quality of life, cardiac arrhythmias and treatments, venous thromboembolism diagnosis and management, as well as diabetes, cardiovascular risks, and lipoproteins.

Giugliano has published extensively in a number of prestigious journals. Frequent publication venues include:

  • Circulation
  • Journal of the American College of Cardiology
  • European Heart Journal
  • JAMA Cardiology
  • American Heart Journal

Frequent coauthors reflect ongoing collaborations within the cardiovascular research community. These include:

  • Marc S. Sabatine
  • Christian T. Ruff
  • Sabina A. Murphy
  • Eugene Braunwald
  • Elliott M. Antman

Among recent publications, the following papers are notable for their relevance and citation impact:

  • Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease, 2022, Circulation
  • Lipoprotein(a) and its Significance in Cardiovascular Disease, 2022, JAMA Cardiology
  • Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials, 2020, The Lancet
  • Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis, 2021, JAMA Cardiology
  • Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis, 2020, Stroke

Giugliano's research addresses critical issues in lipid management, cardiovascular disease prevention, and stroke risk reduction. Their contributions span clinical trials, systematic reviews, and meta-analyses, advancing knowledge in therapies targeting lipoprotein levels and cardiovascular outcomes.

Best Publications

  • Edoxaban versus warfarin in patients with atrial fibrillation

    Robert P. Giugliano;Christian T. Ruff;Eugene Braunwald;Sabina A. Murphy

  • Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

    Marc S. Sabatine;Robert P. Giugliano;Anthony C. Keech;Narimon Honarpour

  • Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

    Christian T Ruff;Robert P Giugliano;Eugene Braunwald;Elaine B Hoffman

  • TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy.

    David A. Morrow;Elliott M. Antman;Andrew Charlesworth;Richard Cairns

  • Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

    Michael G. Silverman;Brian A. Ference;Kyungah Im;Stephen D. Wiviott

  • Abciximab Facilitates the Rate and Extent of Thrombolysis Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial

    Elliott M. Antman;Robert P. Giugliano;C. Michael Gibson;Carolyn H. McCabe

  • Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes

    Marc S. Sabatine;David A. Morrow;Robert P. Giugliano;Paul B.J. Burton

  • Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.

    Michelle L. O’Donoghue;Sergio Fazio;Robert P. Giugliano;Erik S.G. Stroes

  • Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

    Marc P. Bonaca;Patrice Nault;Robert P. Giugliano;Anthony C. Keech

  • Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes

    Brian A. Ference;Jennifer G. Robinson;Robert D. Brook;Alberico L. Catapano

  • Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

    Christian T. Ruff;Robert P. Giugliano;Elliott M. Antman;Sharon E. Crugnale

  • Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

    Robert P. Giugliano;Terje R. Pedersen;Jeong Gun Park;Gaetano M. De Ferrari

  • Early versus delayed, provisional eptifibatide in acute coronary syndromes.

    Robert P. Giugliano;Jennifer A. White;Christoph Bode;Paul W. Armstrong

  • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

    Robert P Giugliano;Nihar R Desai;Payal Kohli;William J Rogers

  • TNK–Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction Results of the TIMI 10B Trial

    Christopher P. Cannon;C. Michael Gibson;Carolyn H. McCabe;A. A. Jennifer Adgey

  • Cognitive Function in a Randomized Trial of Evolocumab

    Robert P. Giugliano;François Mach;Kenton Zavitz;Christopher Kurtz

  • Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

    Marc S Sabatine;Lawrence A Leiter;Stephen D Wiviott;Robert P Giugliano

  • Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

    M.S. Sabatine;R.P. Giugliano;S.D. Wiviott

  • Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

    Christian T Ruff;Robert P Giugliano;Eugene Braunwald;David A Morrow

  • Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.

    Christopher P. Cannon;Robert P. Giugliano;Michael A. Blazing;Robert A. Harrington

Frequent Co-Authors

Eugene Braunwald
Eugene Braunwald Harvard Medical School
Elliott M. Antman
Elliott M. Antman Brigham and Women's Hospital
Sabina A. Murphy
Sabina A. Murphy Brigham and Women's Hospital
Marc S. Sabatine
Marc S. Sabatine Brigham and Women's Hospital
Christopher P. Cannon
Christopher P. Cannon Brigham and Women's Hospital
C. Michael Gibson
C. Michael Gibson Beth Israel Deaconess Medical Center
David A. Morrow
David A. Morrow Brigham and Women's Hospital
Stephen D. Wiviott
Stephen D. Wiviott Brigham and Women's Hospital
Robert A. Harrington
Robert A. Harrington Cornell University
Anthony C. Keech
Anthony C. Keech University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens the door to a variety of rewarding careers beyond the traditional MD route. Busy professionals or those looking for alternative entry points might consider fast track LPN programs online. These allow students to quickly become Licensed Practical Nurses, gaining essential hands-on experience and entering the workforce sooner.

Mental health is a growing field with a strong need for qualified professionals. For those interested in advanced nursing roles, fast track mental health nursing programs let you specialize as a Psychiatric Mental Health Nurse Practitioner much faster than traditional options.

The healthcare sector also needs strong leadership and management. If you’re considering the business side of healthcare, health administration degrees online deliver the flexibility to study while working. Competitive tuition rates make these pathways realistic for more students. For advanced leadership roles, an affordable mha online helps you prepare for executive positions without a hefty financial burden.

These diverse degrees and career paths offer flexibility, affordability, and the ability to make a real impact in healthcare—both clinical and administrative.

Best Scientists Citing Robert P. Giugliano

Trending Scientists

Recently Published Articles